Transaction will give Patheon two biologic plants in the US
DPx Holdings, a global contract development and manufacturing organisation owned by JLL Partners and Royal DSM, has agreed to buy Gallus BioPharmaceuticals, a contract manufacturing company specialising in biologics and currently owned by Ridgemont Equity Partners.
No financial details have been disclosed.
The transaction will provide DPx Holdings' company Patheon with its first biologic plants in the US.
DPx Holdings was formed in March this year and combines DSM Pharmaceutical Products (DPP), Patheon and Banner Life Sciences.
Gallus has a biologics facility in St Louis, MO, which handles commercial cGMP manufacturing, plus a facility in Princeton, NJ, which handles process development and clinical manufacturing of bulk and aseptic-filling of mAbs, as well as large and complex proteins such as Fc-fusion proteins, IgMs and collagens.
Following the transaction, Patheon’s biologic drug substance business will include four facilities in Europe, Australia and North America and include 550 employees globally.
The Patheon pharma services business provides commercial manufacturing, pharmaceutical product development services for solid and sterile dosage forms, and biologic and chemical drug substance development and manufacturing.
We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two US sites
The addition of Gallus will turn Patheon into a leading provider of process development as well as clinical and commercial scale manufacturing of mammalian cell culture-derived products. The company can offer a range of disposable manufacturing technology, as well as commercial scale production.
'We are pleased to expand our biologics business with the acquisition of Gallus BioPharmaceuticals,' said Jim Mullen, CEO of DPx Holdings. 'This transaction is in line with our strategy. We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two US sites.'
Once the transaction is complete, the two Gallus sites will be the first Patheon biologic drug substance facilities in the US and will complement its plants in Groningen, the Netherlands and Brisbane, Australia.
Three of Patheon's four sites each have nearly 30 years of mammalian cell culture experience, while the fourth site in Brisbane was opened within the last year. Together these sites will support Patheon’s ongoing growth in biologics. In addition, the company will be able to leverage its expertise in disposable technology to speed up manufacturing as well as expand its capabilities in mid-scale flexible manufacturing.
'This is an exciting time as we join a world-class company and expand our offerings as one global team specialising in biologics,' said Mark Bamforth, President and CEO of Gallus BioPharmaceuticals.
'We have built deep commercial and clinical manufacturing and process development capabilities that are highly complementary to Patheon’s biologics organisation. We look forward to the ongoing success and growth by combining our knowledge, skills, technical expertise and capabilities to serve customers’ product needs.'
Subject to regulatory approvals, the transaction is expected to close in the fourth quarter.